Improving Pharmacokinetic-Pharmacodynamic Modeling to Investigate Anti-Infective Chemotherapy with Application to the Current Generation of Antimalarial Drugs

PLoS Computational Biology

Volumn 9, Issue 7, 2013, Pages

  Kay, Katherine ^a   Hastings, Ian M ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DISEASE CONTROL; DISEASES;

ANTI-INFECTIVES; ANTIMALARIAL DRUG; ARTEMISININ; COMBINATION THERAPY; COMPUTATIONAL TECHNIQUE; CURRENT GENERATION; INFECTIOUS DISEASE; MECHANISM-BASED; MODE OF ACTION; PHARMACOKINETIC PHARMACODYNAMIC MODELS;

PHARMACOKINETICS;

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; DRUG METABOLITE;

ARTICLE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CONCENTRATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESISTANCE; DRUG THERAPY; DRUG TOLERANCE; DRUG TRANSFORMATION; INTESTINE ABSORPTION; INTESTINE WALL; MALARIA FALCIPARUM; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MONOTHERAPY; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMODIUM FALCIPARUM;

ARTESUNATE;

EID: 84880823096     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003151     Document Type: Article

References (49)

1. Czock D, Keller F, (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 34: 727-751.
2. World Health Organisation (2008) The global burden of disease (2004 update). 1-160.
3. World Health Organisation (2010) Guidelines for the treatment of malaria. second edition. 1-196 p.
4. Attaran A, (2004) Rescuing malaria treatment, or not? Lancet 364: 1922-1923.
5. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, et al. (2010) Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8: 272-280.
6. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455-467.
7. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, et al. (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 2619-2620.
8. Wongsrichanalai C, Meshnick SR, (2008) Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerging Infect Dis 14: 716-719.
9. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, et al. (2009) Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. PLoS ONE 4: e4551.
10. Burki T, (2009) Artemisinin resistance could endanger fight against malaria. Lancet 9: 213.
11. Enserink M, (2010) Malaria's drug miracle in danger. Science 328: 844-846.
12. Jaki T, Parry A, Winter K, Hastings I, (2012) Analysing malaria drug trials on a per-individual or per-clone basis: a comparison of methods. Stat Med doi:10.1002/sim.5706.
13. Winter K, Hastings IM, (2011) Development, evaluation and application of an in silico model for antimalarial drug treatment failure. Antimicrob Agents 55: 3380-3392.
14. Hoshen M, Stein W, Ginsburg H, (1998) Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Parasitology 116: 407-416.
15. Hoshen MB, Stein WD, Ginsburg HD, (2001) Pharmacokinetic-pharmacodynamic modelling of the anti-malarial activity of mefloquine. Parasitology 123: 337-346.
16. Austin D, White N, Anderson R, (1998) The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol 194: 313-339.
17. Simpson J, Watkins E, Price R, Aarons L, Kyle D, et al. (2000) Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents 44: 3414-3424.
18. Mayersohn M, Gibaldi M, (1970) Mathematical methods in pharmacokinetics. Use of the laplace transformation for solving differential equations. Amer J Pharm Ed 34: 608-614.
19. Simpson JA, Jamsen KM, Price RN, White NJ, Lindegardh N, et al. (2009) Towards optimal design of anti-malarial pharmacokinetic studies. Malar J 8: 189.
20. Chou TC, (2006) Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews 58: 621-681.
21. Gatton ML, Martin LB, Cheng Q, (2004) Evolution of Resistance to Sulfadoxine-Pyrimethamine in Plasmodium falciparum. Antimicrob Agents 48: 2116-2123.
22. Mu J, Myers RA, Jiang H, Liu S, Ricklefs S, et al. (2010) Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet 42: 268-271.
23. White NJ, (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents 41: 1413-1422.
24. Zaloumis S, Humberstone A, Charman SA, Price RN, Moehrle J, et al. (2012) Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malaria Journal 11: 303.
25. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, et al. (2004) Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363: 9-17.
26. World Health Organisation (2009) Global Malaria Control and Elimination: report of a meeting on containment of artemisinin tolerance. 1-38.
27. Hastings I, (2011) How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends Parasitol 27: 67-72.
28. Anderson Tim JC, Nair S, Nkhoma S, Williams Jeff T, Imwong M, et al. (2010) High Heritability of Malaria Parasite Clearance Rate Indicates a Genetic Basis for Artemisinin Resistance in Western Cambodia. J Infect Dis 201: 1326-1330.
29. Sowunmi A, Adewoye EO, Gbotsho GO, Happi CT, Sijuade A, et al. (2010) Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malar J 9: 1-11.
30. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, et al. (2010) Artemisinin resistance in Cambodia: A clinical trial designed to address an emerging problem in southeast Asia. Clin Infect Dis 51: e82-e89.
31. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, et al. (2011) The threat of artemisinin-resistant malaria. N Engl J Med 365: 1073-1075.
32. Ecker A, Lehane AM, Clain J, Fidock DA, (2012) Pfcrt and its role in antimalarial drug resistance. Trends Parasitol 28: 504-514.
33. Brockman A, Price RN, Van Vugt M, Heppner DG, Walsh D, et al. (2000) Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg 94: 537-544.
34. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, et al. (2011) Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci 108: 397-402.
35. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H, (2000) Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 121: 237-246.
36. Zaloumis S, Humberstone A, Charman S, Price R, Moehrle J, et al. (2012) Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malaria Journal 11: 303.
37. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, et al. (2011) Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 108: 397-402.
38. Patel K, Batty KT, Moore BR, Gibbons PL, Bulitta JB, et al. (2012) Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria. Antimicrob Agents Chemother (Ahead of print: AAC.01463-12).
39. Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB, (2009) The time course of drug effects. Pharm Stat 8: 176-185.
40. Winter K, Hastings IM, (2011) Development, evaluation and application of an in silico model for antimalarial drug treatment and failure. Antimicrobial Agents & Chemotherapy 55: 3380-3392.
41. Stepniewska K, White NJ, (2008) Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents 52: 1589-1596.
42. Tan B, Naik H, Jang I-J, Yu K-S, Kirsch LE, et al. (2009) Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malar J 8.
43. Hastings IM, Watkins WM, (2006) Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 22: 71-77.
44. Hastings IM, Watkins WM, White NJ, (2002) The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc B: Biol Sci 357: 505-519.
45. Watkins WM, Mosobo M, (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87: 75-78.
46. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, et al. (2012) The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites. PLoS Med 9: e1001169.
47. Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, et al. (2000) Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents 44: 972-977.
48. vanAgtmael MA, Cheng-Qi S, Qing JX, Mull R, Boxtel CJv, (1999) Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 12: 151-158.
49. Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, Mayanja-Kizza H, Katabira E, et al. (2012) Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother 67: 1217-23.